Clinical Trials Logo

Cerebral Small Vessel Diseases clinical trials

View clinical trials related to Cerebral Small Vessel Diseases.

Filter by:

NCT ID: NCT03542734 Recruiting - Clinical trials for Cognitive Dysfunction

Cognitive Impairment, Retinopathy, and Cerebrovascular Lesions in the Elderly

CIRCLE
Start date: January 1, 2010
Phase:
Study type: Observational [Patient Registry]

The CIRCLE study is a single-center prospective observational study that enrolled individuals with cerebral small vessel disease (SVD), while free of known dementia or stroke (both cerebral infarction and hemorrhage). The patients will receive neuropsychological testing, retinal digital images and multimodal magnetic resonance imaging (MRI). Blood samples will also be collected. Recent small subcortical infarcts, lacunes, white matter hyperintensities, perivascular spaces, microbleeds, and brain atrophy will be evaluated on both baseline and follow-up brain MRIs. The investigators will explore the predictors of preogression of SVD and cognitive deficits.

NCT ID: NCT03451591 Completed - Clinical trials for Cerebral Small Vessel Diseases

LACunar Intervention (LACI-2) Trial-2

LACI-2
Start date: January 8, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

About 35,000 people each year in the UK have a type of stroke, called 'lacunar' or 'small vessel' stroke, which is different to other common types of stroke and for which there is no proven treatment. It is thought that small vessel stroke is caused by damage to the lining of the tiny blood vessels deep inside the brain that stops them functioning normally. This not only causes stroke but, perhaps more importantly, causes problems with thinking and walking, possibly causing up to 45% of all dementias either on its own, or mixed with Alzheimer's disease (about 350,000 patients in the UK). Some drugs that are commonly used in other blood vessel diseases may help improve small vessel function and prevent worsening of brain damage. One drug (cilostazol) has been tested in patients with stroke in the Asia Pacific countries but not on dementia; the other drug (isosorbide mononitrate) is widely used in the UK for heart disease but not stroke. The investigators want to set up a clinical trial to test if the study methods are practical so that patients and trial centres can follow the procedures, and to confirm how many patients have more stroke-like symptoms or experience worsening of their thinking skills. This information is needed to be sure that a very large clinical trial to find out if these drugs can prevent worsening of small vessel disease will be possible.

NCT ID: NCT03153150 Completed - Atrial Fibrillation Clinical Trials

Start or STop Anticoagulants Randomised Trial (SoSTART)

SoSTART
Start date: March 28, 2018
Phase: Phase 3
Study type: Interventional

Primary research question: For adults surviving spontaneous (non-traumatic) symptomatic intracranial haemorrhage with persistent/paroxysmal atrial fibrillation/flutter (AF), does starting full treatment dose oral anticoagulation (OAC) result in a beneficial net reduction of all serious vascular events compared with not starting OAC? Trial design: Investigator-led, multicentre, randomised, open, assessor-masked, parallel group, clinical trial of investigational medicinal product (CTIMP) prescribing strategies. Investigators plan for a pilot phase, followed by a safety phase.

NCT ID: NCT03082014 Terminated - Clinical trials for Cerebral Small Vessel Diseases

Effects of Amlodipine and Other Blood Pressure Lowering Agents on Microvascular Function

TREAT-SVDs
Start date: February 22, 2018
Phase: Phase 3
Study type: Interventional

Multicentre, multinational, prospective randomised, open-label, 3 sequence crossover phase III b clinical trial with blinded endpoint assessment (PROBE-design) - in 75 patients with sporadic small vessel diseases (SVDs) and - in 30 patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)

NCT ID: NCT02890888 Terminated - Clinical trials for Cerebral Small Vessel Diseases

Effect of Hyperbaric Oxygen on Functional Connectivity in Patients With Cerebral Small Vessel Disease

Start date: November 2014
Phase: N/A
Study type: Interventional

Patients will have a Functional MRI before and after 10 hyperbaric Oxygen treatments.

NCT ID: NCT02801032 Completed - Clinical trials for Cerebral Small Vessel Diseases

Effect of Tadalafil on Cerebral Large Arteries in Stroke

ETLAS
Start date: November 29, 2016
Phase: Phase 2
Study type: Interventional

In a double blind placebo-controlled cross-over study the effect of tadalafil on blood flow velocity in the large arteries of the brain, cortical brain oxygenation, peripheral endothelial function, and endothelial biomarkers will be tested in patients with lacunar stroke caused by cerebral small vessel disease.

NCT ID: NCT02730065 Recruiting - Clinical trials for Cerebrovascular Disease

Aerobic Dance Training in Small Vessel Disease

ADTSVD
Start date: May 2016
Phase: N/A
Study type: Interventional

Introduction: Cerebral small vessel disease (SVD) is associated with age-related disabilities including dementia, depression, physical and functional impairment. Chinese are more prone to developing SVD than Caucasians. Physical exercise may improve multiple negative consequences associated with SVD. Objective and hypothesis to be tested: To examine the effects of a 24-week structured aerobic dance training on cognition, mood, physical and daily functions in stroke and dementia free older adults with SVD, and whether such effects are mediated through improved cerebral vasomotor reactivity (CVR), a marker of cerebral autoregulation which is impaired in SVD. Design and subjects: Rater-blind RCT comparing the effects of 24-week of structured aerobic dance training upon cognition, mood, physical and daily functions on 110 community dwelling, stroke- and dementia-free persons aged ≥65 with MRI evidence of significant SVD, defined as the presence of multiple (≥2) lacunes and/or early confluent or confluent WML. Interventions: Participants are randomized in a 1:1 ratio into a 24-week of structured therapist-led group aerobic dance training with home practice or simple stretching plus health education control group. Main outcome measures: Cognition, mood, physical and daily functions and CVR measured using Transcranial Doppler at baseline, weeks 12, 24 and 36. Data analysis: Intent-to-treat with multiple imputations with treatment efficacy analyzed using mixed effects models. Mediation effects of CVR between aerobic dance training and treatment outcomes tested using mediation models. Expected results: In persons with significant SVD, aerobic dance training improves cognitive, mood, physical and daily functions and such effects are mediated by changes in CVR.

NCT ID: NCT02485275 Completed - Clinical trials for Acute Ischemic Stroke

Stroke Imaging Package Study

SIPS
Start date: July 1, 2015
Phase:
Study type: Observational [Patient Registry]

Our study aims to explore the value of new imaging technique package in predicting early neurological deterioration (END) as well as 90-day unfavorable outcome in patients with acute ischaemic stroke.

NCT ID: NCT02481323 Completed - Stroke Clinical Trials

Lacunar Intervention Trial 1 (LACI-1)

Prevent-SVD
Start date: March 2016
Phase: Phase 2
Study type: Interventional

Phase II pilot randomised, factorial, short term dose escalation, open label, blinded intermediary endpoint trial, in two hospital centres in the UK, of tolerability and safety of cilostazol, isosorbide mononitrate, both or neither in patients with small vessel disease manifest as symptomatic small subcortical stroke.

NCT ID: NCT02232958 Terminated - Encephalopathy Clinical Trials

Effect of HBO on Functional Connectivity of Resting State Networks in Patients With Cerebral Small Vessel Disease

HBO
Start date: September 16, 2014
Phase: N/A
Study type: Interventional

The purpose of this study is to extend our previous work, in which we demonstrated an increase in the internal and cross network connectivity of resting state neural networks in patients with cerebral small vessel disease by treatment with hyperbaric oxygen, to at least 20 more individuals.